Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SOUTH PLAINFIELD, N.J. and ROCHESTER, N.Y., May 09, 2017 -- Today, the University of Rochester School of Medicine and Dentistry and Admera Health announced that enrollment had commenced in a randomized clinical study evaluating the use of pharmacogenomics to guide pain management decisions related to acute dental surgery. Specifically, the study is seeking to determine if a preoperative chair-side pharmacogenomic algorithm can significantly enhance the efficacy of surgical pain management and to characterize the association between gene-drug interactions and clinical outcomes.
Admera Health, a molecular diagnostic company, will extract and sequence DNA samples provided by the University of Rochester. Sequencing will utilize Admera’s PGxOne™ Plus test, a 50 gene Next Generation Sequencing panel that interrogates nearly 200 different variants and provides recommendations for over 220 drugs based on an individual’s unique genetic makeup.
“It is well understood in the medical community that most acute surgical pain methods have shown inconsistent effects on pain relief and rely excessively on opioid use, which has associated dependency issues,” as stated by Admera CEO and President Guanghui Hu. “With the implementation of our PGxOne™ Plus test, we are confident that this study will demonstrate improved patient outcomes, similar to the way pharmacogenomics has been clinically validated in other therapeutic areas such as cardiovascular health, oncology, and psychiatric care. That is why we are excited to be working with the University of Rochester for this study.”
According to the CDC, opioid-involved deaths continue to increase and have reached epidemic status. In March, a United States Senate committee opened a probe into the practices of the top manufacturers of opioid drugs.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
